PTP4A3 and acute lymphoblastic leukemia: Short-term (<2 h) JMS-053 treatment significantly (p < 0.001) impaired the migration capability of all PRL-3 expressing T-ALL cell lines tested, reducing cell migration through a transwell towards a serum stimulus by 30–80% (Fig. 6b).